Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notch(mut))
Ferrarotto, R. Metcalf, Robert Rodriguez, C. P. Muzaffar, J. Even, C. Perez, A. Herpen, C. Oliva, M. Xia, B. Bowles, D. W.
Ferrarotto, R.
Metcalf, Robert
Rodriguez, C. P.
Muzaffar, J.
Even, C.
Perez, A.
Herpen, C.
Oliva, M.
Xia, B.
Bowles, D. W.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Ferrarotto R, Metcalf R, Rodriguez CP, Muzaffar J, Even C, Perez A, et al. Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notch(mut)). Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301747.